JP2013525501A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525501A5
JP2013525501A5 JP2013509268A JP2013509268A JP2013525501A5 JP 2013525501 A5 JP2013525501 A5 JP 2013525501A5 JP 2013509268 A JP2013509268 A JP 2013509268A JP 2013509268 A JP2013509268 A JP 2013509268A JP 2013525501 A5 JP2013525501 A5 JP 2013525501A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cyclodextrin
composition according
pazopanib
modified cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509268A
Other languages
English (en)
Japanese (ja)
Other versions
JP5835717B2 (ja
JP2013525501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035363 external-priority patent/WO2011140343A1/en
Publication of JP2013525501A publication Critical patent/JP2013525501A/ja
Publication of JP2013525501A5 publication Critical patent/JP2013525501A5/ja
Application granted granted Critical
Publication of JP5835717B2 publication Critical patent/JP5835717B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509268A 2010-05-05 2011-05-05 医薬組成物およびその製造方法 Expired - Fee Related JP5835717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05
US61/331,715 2010-05-05
PCT/US2011/035363 WO2011140343A1 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Publications (3)

Publication Number Publication Date
JP2013525501A JP2013525501A (ja) 2013-06-20
JP2013525501A5 true JP2013525501A5 (cg-RX-API-DMAC7.html) 2014-06-26
JP5835717B2 JP5835717B2 (ja) 2015-12-24

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509268A Expired - Fee Related JP5835717B2 (ja) 2010-05-05 2011-05-05 医薬組成物およびその製造方法

Country Status (26)

Country Link
US (3) US20120028918A1 (cg-RX-API-DMAC7.html)
EP (1) EP2566331B1 (cg-RX-API-DMAC7.html)
JP (1) JP5835717B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130071434A (cg-RX-API-DMAC7.html)
CN (1) CN102970871A (cg-RX-API-DMAC7.html)
AR (1) AR081364A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011247995B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012028291A2 (cg-RX-API-DMAC7.html)
CA (1) CA2798386A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012003075A1 (cg-RX-API-DMAC7.html)
CO (1) CO6640262A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120556A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000281A (cg-RX-API-DMAC7.html)
EA (1) EA201291168A1 (cg-RX-API-DMAC7.html)
ES (1) ES2519615T3 (cg-RX-API-DMAC7.html)
IL (1) IL222751A0 (cg-RX-API-DMAC7.html)
MA (1) MA34286B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012012837A (cg-RX-API-DMAC7.html)
NZ (1) NZ603411A (cg-RX-API-DMAC7.html)
PE (1) PE20130217A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012502159A1 (cg-RX-API-DMAC7.html)
SG (1) SG185087A1 (cg-RX-API-DMAC7.html)
TW (1) TW201206908A (cg-RX-API-DMAC7.html)
UY (1) UY33367A (cg-RX-API-DMAC7.html)
WO (1) WO2011140343A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201208265B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
LT2600930T (lt) 2010-08-05 2021-04-12 Forsight Vision4, Inc. Injekcinis aparatas, skirtas vaisto tiekimui
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
CA2864736A1 (en) * 2012-02-17 2013-08-22 Pharmacyclics, Inc. Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
AU2013228148B2 (en) * 2012-03-08 2016-07-14 Samsung Electronics Co., Ltd. Method for controlling service in radio communication system
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
WO2016104690A1 (ja) 2014-12-25 2016-06-30 国立大学法人京都大学 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
EP3439591B1 (en) 2016-04-05 2020-09-23 ForSight Vision4, Inc. Implantable ocular drug delivery devices
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
TWI770246B (zh) * 2017-08-02 2022-07-11 昊運股份有限公司 新穎化合物及包含其之醫藥組成物
EP4249069B1 (en) * 2018-06-07 2025-11-19 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
SI1968594T1 (sl) * 2005-11-29 2011-01-31 Glaxosmithkline Llc Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007121483A2 (en) * 2006-04-18 2007-10-25 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use iv bolus compositions and methods of use
ES2630406T3 (es) * 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
WO2011039648A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same

Similar Documents

Publication Publication Date Title
JP2013525501A5 (cg-RX-API-DMAC7.html)
JP5885670B2 (ja) 黄斑変性の処置のための組成物および方法
HRP20170021T1 (hr) Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
PE20130217A1 (es) Composiciones farmaceuticas y metodos para su elaboracion
AR070824A1 (es) Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas
JP2011513492A5 (cg-RX-API-DMAC7.html)
JP2017527623A5 (cg-RX-API-DMAC7.html)
CA2760140C (en) Topical solution formulations containing a corticosteroid and a cyclodextrin
JP2015527402A5 (cg-RX-API-DMAC7.html)
EA201370175A1 (ru) Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
AU2003230681A1 (en) Use of sulfoalkyl ether cyclodextrin as a preservative
JP2019507756A5 (cg-RX-API-DMAC7.html)
JP2018021007A5 (cg-RX-API-DMAC7.html)
JP2013513612A5 (cg-RX-API-DMAC7.html)
HRP20191369T1 (hr) Farmaceutski pripravak koji sadrži antivirusni derivat dihidrokvinazolina
RU2018117935A (ru) Водная композиция, содержащая дантролен
KR950016717A (ko) 제약 조성물
JP2016505044A5 (cg-RX-API-DMAC7.html)
HRP20140016T1 (hr) Suspenzije nanoäśestica koje sadrže karboksivinilni polimer
ES2548706T3 (es) Nanosuspensión farmacéutica
WO2010053487A1 (en) Composition containing sulfoalkyl ether cyclodextrin and latanoprost
KR102762379B1 (ko) 안과용 조성물
JP2023502914A (ja) ウルソデオキシコール酸の注射用組成物
JP5205909B2 (ja) 粘膜適用液剤
JP2018526420A5 (cg-RX-API-DMAC7.html)